Indrayani Biotec

Why is Indrayani Biotech Ltd falling/rising?

As of 01-Sep, Indrayani Biotech Ltd's stock price is declining, currently at 7.55, with a total decline of -3.76% over the last three days and significant underperformance against benchmark indices. Weak investor participation and poor financial metrics further indicate concerns about the company's health and sustainability.

As of 01-Sep, Indrayani Biotech Ltd's stock price is falling, currently at 7.55, reflecting a change of -0.26, or -3.33%. The stock has been on a downward trend, having lost value for the last three consecutive days, with a total decline of -3.76% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent weakness in its price performance.<BR><BR>Investor participation has also decreased, as evidenced by a delivery volume of 15.96k on 31 August, which represents a -12.61% drop compared to the 5-day average delivery volume. This decline in trading activity suggests reduced interest from investors, further contributing to the stock's downward movement.<BR><BR>From a broader perspective, Indrayani Biotech Ltd has consistently underperformed against the benchmark indices, with a year-to-date decline of -33.24% compared to the Sensex's -9.71%. Over the past three years, the stock has plummeted by -85.72%, while the benchmark has gained 17.67%. This long-term underperformance, coupled with weak fundamental indicators such as a high Debt to EBITDA ratio of 18.52 times and low Return on Capital Employed (ROCE) of 1.3, raises concerns about the company's financial health and ability to generate sustainable returns.<BR><BR>Overall, the combination of declining stock price, reduced investor participation, and poor long-term performance metrics are key factors contributing to the falling stock price of Indrayani Biotech Ltd.

Who are in the management team of Indrayani Biotec?

The management team of Indrayani Biotec includes Executive Director Kasiraman Sayee Sundar, Whole-time Directors Singarababu Indirakumar, Muthu Krishnan Ramesh, and G Swaminathan, along with Independent Directors K S Vaidyanathan, N M Ranganathan, and B N Padmaja Priyadarshini, Non-Executive Director Lakshmi Prabha, and Company Secretary Rajesh Kumar. They oversee the company's operations and strategic direction.

The management team of Indrayani Biotec includes the following individuals:<BR><BR>1. **Kasiraman Sayee Sundar** - Executive Director, Managing Director, and Promoter<BR>2. **Singarababu Indirakumar** - Whole-time Director<BR>3. **Muthu Krishnan Ramesh** - Whole-time Director<BR>4. **G Swaminathan** - Whole-time Director<BR>5. **K S Vaidyanathan** - Independent Non-Executive Director<BR>6. **Lakshmi Prabha** - Non-Executive and Non-Independent Director<BR>7. **N M Ranganathan** - Chairman and Independent Director<BR>8. **B N Padmaja Priyadarshini** - Independent Non-Executive Director<BR>9. **Rajesh Kumar** - Company Secretary and Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Indrayani Biotec do?

Indrayani Biotech Ltd is a micro-cap company in the Other Agricultural Products industry, specializing in cut flowers, strawberries, tissue culture plantlets, and hybrid vegetable seeds. As of March 2026, it reported net sales of 73 Cr and a net profit of 1 Cr, with a market cap of INR 60 Cr.

Overview:<BR>Indrayani Biotech Ltd operates in the Other Agricultural Products industry as a micro-cap company, focusing on the production of cut flowers, strawberries, tissue culture plantlets, and hybrid vegetable seeds.<BR><BR>History:<BR>Indrayani Biotech Limited was incorporated in 1992 and went public in 1994 to partially finance its agricultural projects. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 73 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 60 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 37.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.70 <BR>Return on Equity: 2.28% <BR>Price to Book: 0.85 <BR><BR>Contact Details:<BR>Address: 1133/5 F C Road, Opp Police Grounds Pune Maharashtra : 411016 <BR>Tel: 91-20-25662021 <BR>Email: info@indrayani.com <BR>Website: http://www.indrayani.com

Who are the peers of the Indrayani Biotec?

Indrayani Biotec's peers include Saptarishi Agro, Universal Starch, Himalaya Food, Agri-Tech India, City Crops Agro, Flex Foods, and Unique Organics. In terms of management risk, Unique Organics is rated excellent, while Indrayani Biotec has below average risk; its 1-year return is -32.56%, better than Himalaya Food's -38.67% but worse than Universal Starch's 13.45%.

Peers: The peers of Indrayani Biotec are Saptarishi Agro, Universal Starch, Himalaya Food, Agri-Tech India, City Crops Agro, Flex Foods, and Unique Organics.<BR><BR>Quality Snapshot: Excellent management risk is observed at Unique Organics, while Average management risk is found at Saptarishi Agro, Universal Starch, and Flex Foods. Below Average management risk is noted for Himalaya Food, City Crops Agro, and Indrayani Biotec, while Agri-Tech India does not qualify. In terms of growth, Unique Organics shows good growth, Indrayani Biotec also has good growth, while Saptarishi Agro, Universal Starch, Himalaya Food, City Crops Agro, and Flex Foods exhibit below average growth. Agri-Tech India does not qualify for growth. For capital structure, Unique Organics has a good rating, while Saptarishi Agro, Universal Starch, Indrayani Biotec, and City Crops Agro have below average ratings, and Flex Foods has an average rating.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Universal Starch at 13.45%, while the peer with the lowest is Himalaya Food at -38.67%. Indrayani Biotec's 1-year return is -32.56%, which is higher than Himalaya Food's but lower than Universal Starch's. Additionally, Saptarishi Agro, Himalaya Food, and Unique Organics have negative six-month returns.

How big is Indrayani Biotec?

As of 31st August, Indrayani Biotech Ltd has a market capitalization of 60.00 Cr, with net sales of 172.84 Cr and a net profit of 1.77 Cr reported over the latest four quarters. The balance sheet for March 2025 shows shareholder's funds of 72.51 Cr and total assets of 267.94 Cr.

As of 31st August, Indrayani Biotech Ltd has a market capitalization of 60.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported net sales of 172.84 Cr and a net profit of 1.77 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing shareholder's funds of 72.51 Cr and total assets of 267.94 Cr.

Which are the latest news on Indrayani Biotec?

Should I buy, sell or hold Indrayani Biotech Ltd?

When is the next results date for Indrayani Biotech Ltd?

The next results date for Indrayani Biotech Ltd is 17 August 2026.

The next results date for Indrayani Biotech Ltd is scheduled for 17 August 2026.

Are Indrayani Biotech Ltd latest results good or bad?

Indrayani Biotech Ltd's latest results are concerning, showing a 102.14% revenue growth but a 75% decline in net profit and a deteriorating operating margin. High debt levels and operational inefficiencies indicate significant weaknesses, making it a risky investment.

Indrayani Biotech Ltd's latest results indicate a troubling situation for the company. While it achieved a remarkable revenue growth of 102.14% year-on-year, bringing net sales to ₹35.01 crores, this impressive topline performance is overshadowed by a significant collapse in profitability. The net profit for Q3 FY26 plummeted to just ₹0.06 crores, reflecting a staggering 75% decline compared to the same quarter last year and an 85% drop from the previous quarter.<BR><BR>Moreover, the operating margin has deteriorated sharply to 7.94%, down from 16.86% a year ago. This margin compression indicates rising costs and operational inefficiencies that the company has been unable to manage effectively. Additionally, the debt-to-equity ratio has climbed to a concerning 1.93x, the highest level recorded, further complicating the company's financial health.<BR><BR>Overall, the combination of strong revenue growth but collapsing profits, high debt levels, and deteriorating operational efficiency suggests that the latest results are more bad than good. The company's fundamentals are showing significant weaknesses, making it a risky investment at this time.

How has been the historical performance of Indrayani Biotec?

Indrayani Biotec's historical performance has been volatile, with net sales declining from 166.23 Cr in March 2024 to 130.23 Cr in March 2025, resulting in significant losses, including a profit after tax of -6.11 Cr in March 2025 compared to 10.42 Cr the previous year. The company's earnings per share also fell from 1.4 to -1.34 during this period.

Answer:<BR>The historical performance of Indrayani Biotec has shown significant fluctuations over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Indrayani Biotec's net sales peaked at 166.23 Cr in March 2024 but fell to 130.23 Cr by March 2025. The total operating income followed a similar trend, decreasing from 166.23 Cr in March 2024 to 130.23 Cr in March 2025. The company experienced a notable increase in raw material costs, which reached 82.77 Cr in March 2025, down from 97.13 Cr in March 2024. Operating profit (PBDIT) also declined from 24.66 Cr in March 2024 to 18.36 Cr in March 2025, while profit before tax turned negative at -5.74 Cr in March 2025 after being positive at 10.97 Cr in March 2024. Consequently, the profit after tax also fell to -6.11 Cr in March 2025 from 10.42 Cr in March 2024. The earnings per share (EPS) reflected this downturn, dropping to -1.34 in March 2025 from 1.4 in March 2024. Overall, the company's financial performance has been inconsistent, with significant losses in the most recent fiscal year following a period of profitability.

Is Indrayani Biotec overvalued or undervalued?

As of August 18, 2025, Indrayani Biotec is considered overvalued and risky due to its negative PE ratio of -8.57, high EV to EBITDA ratio of 22.74, and a year-to-date stock return of -63.91%, especially when compared to its peers.

As of 18 August 2025, the valuation grade for Indrayani Biotec has moved from attractive to risky, indicating a significant deterioration in its financial outlook. The company appears to be overvalued based on its current metrics, particularly given its negative PE ratio of -8.57 and an EV to EBIT ratio of -21.70, which are alarming indicators of financial distress. Additionally, the EV to EBITDA ratio stands at 22.74, suggesting that the market is pricing the company at a premium despite its poor earnings performance.<BR><BR>In comparison to its peers, Indrayani Biotec's valuation metrics are starkly unfavorable. For instance, Elegant Floricul is categorized as very expensive with a PE ratio of 18.24, while Trescon also falls into the very expensive category with an EV to EBITDA of -209.83. This stark contrast highlights the challenges faced by Indrayani Biotec, especially with a year-to-date stock return of -63.91% compared to a modest 4.01% return for the Sensex. Overall, the company is deemed overvalued given its current financial ratios and performance relative to its peers.

Who are the top shareholders of the Indrayani Biotec?

The top shareholders of Indrayani Biotec are G Swaminathan, the promoter with 9.09% ownership, and Jayaseelan Singaravelu, the highest public shareholder with 10.11%. Approximately 46.64% of shares are held by individual investors, with no mutual funds or foreign institutional investors involved.

The top shareholders of Indrayani Biotec include G Swaminathan, who is the promoter with the highest holding at 9.09%. Additionally, the highest public shareholder is Jayaseelan Singaravelu, holding 10.11%. The majority of the company's shares, approximately 46.64%, are held by individual investors. It's also noteworthy that there are no mutual funds or foreign institutional investors currently holding shares in the company.

What is the technical trend for Indrayani Biotec?

As of June 5, 2025, Indrayani Biotec's technical trend is bearish with moderate strength, supported by bearish Bollinger Bands and daily moving averages, despite some conflicting signals from the MACD and KST indicators.

As of 5 June 2025, the technical trend for Indrayani Biotec has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. The weekly MACD indicates a mildly bullish signal, but the monthly MACD is bearish, which reflects a conflicting trend. The Bollinger Bands are bearish on both weekly and monthly time frames, reinforcing the bearish outlook. Daily moving averages also confirm a bearish trend. The KST shows a mildly bullish signal on the weekly chart but is bearish monthly, while Dow Theory indicates a mildly bullish stance weekly with no trend monthly. Overall, the indicators suggest a prevailing bearish sentiment, particularly in the longer time frames.

Has Indrayani Biotec declared dividend?

No Dividend History Available